Understanding FDA Type A, B, and C Meetings: Differences and Case Examples

Overview of FDA Pre-Submission Meeting Types

Interacting with the U.S. Food and Drug Administration (FDA) is essential for successful regulatory navigation, especially in drug, biologic, or device development. The agency offers three structured meeting types — Type A, Type B, and Type C — each serving a specific purpose at different points in the product development lifecycle.

Knowing when to request each type and what to expect can significantly influence timelines, clinical program design, and eventual marketing approval.

FDA Type A Meetings: Crisis Resolution or Stalled Programs

Type A meetings are granted to help a sponsor address a stalled development program or to resolve critical regulatory issues that cannot wait. Examples include:

• Dispute resolution after a clinical hold
• Meeting following refusal-to-file (RTF) decision
• Type A meeting following a Complete Response Letter (CRL)

Timelines: FDA schedules these meetings within 30 days of receiving the request. These are generally high priority.

Briefing package: Submitted at the time of meeting request or within 2 days of request acceptance.

FDA Type B Meetings: Key Milestone Interactions

Type B meetings are the most common form of pre-submission interaction. They occur at critical points such as:

• Pre-IND meeting
• End-of-Phase 2 (EOP2) meeting
• Pre-NDA or pre-BLA meeting

These meetings help confirm that safety, efficacy, and CMC strategies align with regulatory expectations.

Timelines: Meeting scheduled within 60 days of request. FDA responds within 14 days of request receipt.

Briefing package: Submitted at least 30 days before the confirmed meeting date.

FDA Type C Meetings: Other Development Topics

Type C meetings are for any topics not falling under Type A or B criteria. Examples include:

• Discussing a novel biomarker development plan
• Seeking clarification on post-marketing study designs
• Requesting early feedback on patient-reported outcomes

These are useful for advancing complex or innovative elements of the development program.

Timelines: Scheduled within 75 days of request; longer than Type A or B.

Continue with a Comparative Table and Real-World Case Studies

Comparative Table: FDA Meeting Types at a Glance

Case Study 1: Type A Meeting to Address CRL

A company received a Complete Response Letter (CRL) for a small-molecule oncology product due to concerns about CMC variability and missing safety data in an elderly subpopulation. A Type A meeting was requested to:

• Clarify what additional clinical trials were required
• Negotiate if bridging data could be used
• Understand timeline for resubmission

The meeting led to FDA agreement on a targeted patient population and allowed for re-analysis using real-world data, ultimately leading to a successful NDA resubmission.

Case Study 2: Type B Pre-IND Meeting

A biotech firm working on a monoclonal antibody for rare autoimmune disease held a pre-IND Type B meeting to:

• Confirm nonclinical study adequacy
• Discuss proposed starting dose in first-in-human study
• Clarify the need for additional reproductive toxicology studies

The company received valuable input, avoiding an unnecessary animal study and confirming their clinical protocol design.

Case Study 3: Type C Meeting on Patient-Reported Outcomes

A sponsor sought feedback on a new quality-of-life endpoint for a chronic pain study. Since this topic didn’t qualify for Type A or B, a Type C meeting was arranged. FDA provided:

• Recommendations on endpoint validation strategy
• Advice on integrating PROs into labeling claims

This early input helped secure FDA agreement on PRO methodology, critical to Phase 3 success.

Strategic Considerations for Meeting Type Selection

Type A: Use judiciously for major regulatory roadblocks. These meetings are rare and require strong justification.

Type B: Always plan ahead. These should be part of your regulatory roadmap and aligned with key submission milestones.

Type C: Ideal for innovative development approaches, risk assessments, or clarifications not tied to formal submissions.

External References and Tools

For examples of meeting types used in global regulatory submissions, visit the Australian New Zealand Clinical Trials Registry to review trial protocols and regulatory pathways involving early agency engagement.

Conclusion: Matching Meeting Type to Development Stage

Properly identifying and requesting the right type of FDA meeting is critical to a sponsor’s regulatory success. Each meeting type serves a distinct purpose, with differing expectations for timelines, content, and feedback. Regulatory teams should develop a long-term meeting strategy, integrated with their submission plan and product development milestones.

When planned effectively, these meetings serve not just as checkpoints but as accelerators toward successful product approval.

Leveraging FDA Meeting Types for Strategic Regulatory Success

Introduction to FDA Meeting Types

The U.S. Food and Drug Administration (FDA) offers several types of formal meetings to help sponsors and applicants navigate the complex regulatory landscape. These meetings are not only regulatory checkpoints but also strategic tools that can streamline drug development and facilitate smoother submissions. Understanding when and how to request these meetings—especially the distinctions between Type A, Type B, and Type C—is crucial to maximizing their value.

These meetings apply across Investigational New Drug (IND), New Drug Application (NDA), Biologics License Application (BLA), and Abbreviated New Drug Application (ANDA) contexts. The primary objective is to obtain FDA feedback that guides development strategies and ensures regulatory compliance throughout the product lifecycle.

Type A Meeting: Addressing Critical Program Stoppages

A Type A meeting is the most urgent of the FDA’s meeting categories. It is typically reserved for resolving clinical holds, addressing disputes, or discussing necessary steps after the FDA has issued a refusal to file a marketing application.

Strategic Use: Sponsors use Type A meetings to seek guidance during major roadblocks in their development programs. Because this type of meeting is focused on immediate resolution, it must be requested with compelling justification and complete documentation of the issue at hand.

Timelines: FDA schedules Type A meetings within 30 calendar days of receiving the meeting request.

Type B Meeting: The Most Common and Strategic FDA Interaction

Type B meetings are the most frequently requested meetings and include:

• Pre-IND meetings
• End-of-Phase 1 (EOP1) and End-of-Phase 2 (EOP2) meetings
• Pre-NDA or Pre-BLA meetings

These meetings occur at critical junctures in the development lifecycle. For example, a pre-IND meeting helps shape the study design and regulatory expectations, while a pre-NDA meeting helps finalize submission strategies.

Strategic Value: These interactions help sponsors avoid costly errors, design better clinical studies, and clarify data expectations. A pre-NDA meeting, for instance, can validate whether your CMC and clinical data packages are complete.

Timelines: FDA will schedule Type B meetings within 60 calendar days of a valid request.

Type C Meeting: Addressing Everything Else

Type C meetings are more flexible and cover any topic not addressed by Type A or B meetings. These include:

• Clarification on statistical endpoints
• Questions on post-marketing studies
• Discussion on novel development approaches

Type C meetings are especially useful for emerging therapies and new technologies where the regulatory path may not be clearly defined.

Timelines: FDA schedules Type C meetings within 75 calendar days of receiving a complete meeting request.

Continue with Real-World Applications and Strategic Planning Tips

Real-World Use Cases: Strategic Deployment of FDA Meetings

Consider a scenario where a sponsor developing a gene therapy product encounters difficulty with vector design compatibility for long-term dosing. A Type C meeting allows the team to engage FDA experts in discussing novel preclinical models. Later, a pre-IND Type B meeting aligns their submission expectations and safety package for first-in-human studies.

In another case, an oncology sponsor uses a pre-NDA Type B meeting to confirm that their Phase 3 surrogate endpoints will support accelerated approval. This drastically shortens review timelines and avoids a potential Complete Response Letter (CRL).

Comparing Meeting Types: Strategic Implications

Meeting Request Components

A complete meeting request is essential for approval and scheduling. The request must include:

• Proposed meeting type and justification
• Product name and application type
• Proposed questions and goals of the meeting
• List of attendees (sponsor and FDA)
• Meeting format (teleconference, face-to-face, written response)

Sponsors should avoid vague or excessively broad meeting questions to ensure a focused and productive discussion.

Meeting Preparation: Regulatory Affairs Role

Regulatory Affairs plays a critical role in the following aspects:

• Drafting a well-structured briefing package
• Coordinating with SMEs across CMC, nonclinical, and clinical disciplines
• Simulating meeting Q&A sessions internally
• Ensuring all regulatory precedents are considered

According to ClinicalTrials.gov, engaging regulatory agencies early via Type B meetings improves submission quality and reduces delays.

Best Practices for Maximizing Meeting Value

• Frame questions clearly and contextually
• Provide a summary of development history
• Submit your briefing package at least 30 days before the meeting
• Assign internal note-takers and response coordinators
• Respect FDA’s time—avoid redundant queries

Post-Meeting Follow-Up and Documentation

FDA provides official meeting minutes within 30 days. However, sponsors should take internal notes, identify action items, and circulate summaries promptly. These insights feed into updated regulatory strategy documents and future meeting requests.

If FDA offers a Written Response Only (WRO), treat it with the same level of diligence and update your development plans accordingly.

Conclusion: Aligning Meeting Types with Development Goals

Understanding and strategically using the different FDA meeting types can unlock significant regulatory advantages. Whether resolving a critical issue via a Type A meeting or shaping your NDA through a Type B meeting, these opportunities must be approached with preparation, clarity, and a solid regulatory roadmap.